Book a Meeting

Non-Fucosylated Anti-Human HDPPA04 (BioBet-974ZP) Therapeutic Antibody (CAT#: BioBet-974ZP) Datasheet

Target
HDPPA04
Isotype
IgG
Description
ADCC-Enhanced anti-HDPPA04 is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Indication
Cancer
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced HDPPA04 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
HDPPA04
Full Name
HDPPA04
Alternative Names
HDPPA04
UniProt ID
Q9UK05
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
BioBet-974ZP
Host
Human
Species Reactivity
Human
Description
The antibody that specifically bind HDPPA04 polypeptides, useful for diagnosing and treating diseases, disorders, and conditions related to said HDPPA04, such as neoplastic diseases, blood disorders and infections.
Indication
Cancer

Cancer

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.